Scholarlink

Background <p>Treatment options for refractory idiopathic inflammatory myopathies (IIMs) remain limited, and sustained remission is frequently not achieved with conventional immunosuppression or biologic agents. Chimeric antigen receptor (CAR) T-cell therapy has been approved for multiple refractory hematologic malignancies and is increasingly being explored as an immune reset strategy for autoimmune diseases.</p> Main body <p>This Review synthesizes all available clinical evidence on CAR T-cell therapy in adult and pediatric IIM, with the aim of raising awareness within the rheumatology community regarding its clinical application and providing an evidence-based framework to guide future therapeutic decision-making. Across 10 reports comprising 12 refractory IIM patients, CAR T-cell therapy was associated with rapid improvements in muscle enzymes and strength, meaningful treatment de-escalation with frequent drug-free remission. Safety was generally manageable, with predominantly grade 1–2 cytokine release syndrome, rare immune effector cell-associated neurotoxicity syndrome, and treatable infections. Pharmacokinetic and immunodynamic patterns were consistent, with early in-vivo expansion, rapid B-cell depletion, and reconstitution dominated by naïve and transitional phenotypes.</p> Conclusions <p>Early clinical experience supports CAR T-cell therapy as a promising experimental approach for refractory IIM, but current evidence is limited by small sample sizes, heterogeneous endpoints, and short follow-up. Prospective studies with standardized outcomes, organ-specific assessments, and long-term safety monitoring are required.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A new hope with CAR T-cell therapy for refractory idiopathic inflammatory myopathies: a systematic review

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月18日

查看全文
  • Xueyan Shan,
  • Fengtao Pang,
  • Guochun Wang,
  • Yongpeng Ge,
  • Xin Lu

摘要

Background

Treatment options for refractory idiopathic inflammatory myopathies (IIMs) remain limited, and sustained remission is frequently not achieved with conventional immunosuppression or biologic agents. Chimeric antigen receptor (CAR) T-cell therapy has been approved for multiple refractory hematologic malignancies and is increasingly being explored as an immune reset strategy for autoimmune diseases.

Main body

This Review synthesizes all available clinical evidence on CAR T-cell therapy in adult and pediatric IIM, with the aim of raising awareness within the rheumatology community regarding its clinical application and providing an evidence-based framework to guide future therapeutic decision-making. Across 10 reports comprising 12 refractory IIM patients, CAR T-cell therapy was associated with rapid improvements in muscle enzymes and strength, meaningful treatment de-escalation with frequent drug-free remission. Safety was generally manageable, with predominantly grade 1–2 cytokine release syndrome, rare immune effector cell-associated neurotoxicity syndrome, and treatable infections. Pharmacokinetic and immunodynamic patterns were consistent, with early in-vivo expansion, rapid B-cell depletion, and reconstitution dominated by naïve and transitional phenotypes.

Conclusions

Early clinical experience supports CAR T-cell therapy as a promising experimental approach for refractory IIM, but current evidence is limited by small sample sizes, heterogeneous endpoints, and short follow-up. Prospective studies with standardized outcomes, organ-specific assessments, and long-term safety monitoring are required.